Press release
Hodgkin Lymphoma Pipeline Outlook Report 2025: Tracking the Most Promising Drugs in Clinical Development | DelveInsight
Curious about the latest updates in the Hodgkin Lymphoma Pipeline? Click here to explore the therapies and trials making headlines @ Hodgkin Lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hodgkin Lymphoma Pipeline Report
* On 22 October 2025, University College, London conducted a phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand.
* On 21 October 2025, Novartis Pharmaceuticals announced a phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
* DelveInsight's Hodgkin Lymphoma Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin Lymphoma treatment.
* The leading Hodgkin Lymphoma Companies such as Merck Sharp & Dohme LLC, Gilead Sciences, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco and others.
* Promising Hodgkin Lymphoma Therapies such as Brentuximab Vedotin, Etoposide, Cyclophosphamide, PF-3512676, Gemcitabine, Nivolumab, Glofitamab, Atezolizumab, Obinutuzumab and others.
Want to know which companies are leading innovation in Hodgkin Lymphoma? Dive into the full pipeline insights @ Hodgkin Lymphoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Hodgkin Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hodgkin Lymphoma Pipeline Report also highlights the unmet needs with respect to the Hodgkin Lymphoma.
Hodgkin Lymphoma Overview
Hodgkin Lymphoma also known as Hodgkin disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is the most common type of cancer of lymphatic system. Hodgkin disease originate in the WBCs and grow abnormally and spread beyond the lymphatic system. As the disease progress it invades into other organs and can damage their function. Hodgkin's lymphoma are more common in men than women and affect individuals between the age of 15-40 and above 55 years. The exact etiology of Hodgkin's Lymphoma is not clear however, DNA mutation, and infection of Epstein-Barr virus (EBV), which causes mononucleosis can be the reason behind the development of Hodgkin's lymphoma.
Hodgkin Lymphoma Emerging Drugs Profile
* AB-205: Angiocrine Bioscience
AB-205 is a first-in-class engineered cell therapy consisting of proprietary 'universal' E-CEL (human engineered cord endothelial) cells. The AB-205 cells are intravenously administered after the completion of HDT on the same day as when the patient's own (autologous) blood stem cells are infused. AB-205 acts promptly to repair injured vascular niches of organs damaged by HDT. By repairing the vascular niches, AB-205 restores the natural process of tissue renewal, vital for organs such as oral-GI tract and the bone marrow. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hodgkin's Lymphoma.
* Magrolimab: Gilead Sciences
Magrolimab is a humanized IgG4 subclass monoclonal antibody. The drug candidate is administered through intravenous route. It acts by targeting CD47 antigen and works as CD47 antigen inhibitors, antibody-dependent cell cytotoxicity. Currently being evaluated in the Phase II studies.
* AUR105 : Aurigene Oncology
AUR105 is an oral, small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). AUR-105 had been found to be safe in preclinical toxicology evaluations, at several fold of anticipated efficacious doses in humans. Currently, the drug is being evaluated in Phase I for the treatment of Hodgkin's Lymphoma.
If you're tracking ongoing Hodgkin Lymphoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Hodgkin Lymphoma Treatment Drugs [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Hodgkin Lymphoma Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin Lymphoma Treatment.
* Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin Lymphoma market.
Hodgkin Lymphoma Companies
Merck Sharp & Dohme LLC, Gilead Sciences, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco and others
Hodgkin Lymphoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Hodgkin Lymphoma Products have been categorized under various Molecule types such as,
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
From emerging drug candidates to competitive intelligence, the Hodgkin Lymphoma Pipeline Report covers it all - check it out now @ Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hodgkin Lymphoma Pipeline Report
* Coverage- Global
* Hodgkin Lymphoma Companies- Merck Sharp & Dohme LLC, Gilead Sciences, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco and others
* Hodgkin Lymphoma Therapies- Brentuximab Vedotin, Etoposide, Cyclophosphamide, PF-3512676, Gemcitabine, Nivolumab, Glofitamab, Atezolizumab, Obinutuzumab and others.
* Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Hodgkin Lymphoma Treatment landscape in this detailed analysis @ Hodgkin Lymphoma Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hodgkin's Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* AB-205: Angiocrine Bioscience
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Magrolimab: Gilead Sciences
* Early Stage Products (Phase I)
* AUR105 : Aurigene Oncology
* Inactive Products
* Hodgkin's Lymphoma Key Companies
* Hodgkin's Lymphoma Key Products
* Hodgkin's Lymphoma- Unmet Needs
* Hodgkin's Lymphoma- Market Drivers and Barriers
* Hodgkin's Lymphoma- Future Perspectives and Conclusion
* Hodgkin's Lymphoma Analyst Views
* Hodgkin's Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hodgkin-lymphoma-pipeline-outlook-report-2025-tracking-the-most-promising-drugs-in-clinical-development-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hodgkin-lymphoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hodgkin Lymphoma Pipeline Outlook Report 2025: Tracking the Most Promising Drugs in Clinical Development | DelveInsight here
News-ID: 4241447 • Views: …
More Releases from ABNewswire
Oral Surgeon Huntington Beach Practice Elevates Standards for Patient Comfort an …
Huntington Beach oral surgery practice, The Wisdom Teeth Guru sets new patient care standards through specialized training, advanced sedation options, and efficient same-day treatment capabilities under Dr. Kiet Tran's leadership.
A Huntington Beach dental practice has gained recognition for transforming how patients experience oral surgery procedures. The Wisdom Teeth Guru [https://www.google.com/maps/place/The+Wisdom+Teeth+Guru/data=!4m2!3m1!1s0x0:0x98592ab69d239d3a?sa=X&ved=1t:2428&hl=en&ictx=111], led by Dr. Kiet Tran, has established new benchmarks in patient care through advanced techniques and a commitment to making…
Columbus Moving Services Expands as Moving Ahead Services Responds to Central Oh …
Moving Ahead Services expands coverage across 23 Central Ohio communities, offering flexible moving solutions with regulatory compliance and community partnerships that support both residential and commercial relocations.
The Central Ohio region continues to experience steady population growth, and Moving Ahead Services has positioned itself to address the increasing demand for professional relocation assistance. The expansion of Columbus moving services reflects the company's two decades of experience serving the area, with operations…
What Does a Full-Service Move Include? Moving Companies Report Surge in Demand f …
Greenville homeowners increasingly prefer comprehensive relocation packages that handle packing, furniture assembly, transportation, and setup. Professional services reduce stress and damage while streamlining transitions.
Homeowners and renters across Greenville are opting for comprehensive relocation packages as the complexity of modern moves continues to grow. Recent trends show that families and businesses alike are seeking moving companies for an end-to-end solution that eliminates the stress traditionally associated with changing addresses. This shift…
Local Garage Door Company Sees Surge in Emergency Repairs Following Extreme Temp …
AA Garage Door LLC reports increased emergency repairs across St. Paul as extreme cold causes cable failures and spring breaks. Technicians respond to urgent service needs throughout Twin Cities neighborhoods affected by harsh winter conditions.
Recent weather patterns across the St. Paul region have created unprecedented challenges for homeowners, with plummeting temperatures causing significant strain on residential overhead door systems. AA Garage Door LLC, a trusted garage door company [https://maps.google.com/maps?ll=44.91738,-93.190993&z=16&t=h&hl=en&gl=PH&mapclient=embed&cid=15111651982362415047&q=garage+door+company&oq=garage+door+company+near+me] serving…
More Releases for Hodgkin
Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph
According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%.
Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/
Key Highlights
Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70…
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth…
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The non hodgkin…
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067
Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides…
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)…
